Treatment of rheumatoid arthritis (RA) with anti-TNF-α antibody (Remicade). Individual monitoring of bioavailability and immunogenicity - Secondary publication;Behandling af reumatoid artrit med anti-tumornekrosefaktor-α- antistof. Individuel monitorering af biotilgængelighed og immunogenicitet - Sekundærpublikation

Ugeskrift for Laeger

Volumn 169, Issue 5, 2007, Pages 420-423

  Bendtzen, Klaus ^a   Geborek, Pierre ^a   Svenson, Morten ^a   Larsson, Lotta ^a   Kapetanovic, Meliha C ^a   Saxne, Tore ^a  

^a International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33846922580     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Maini RN, Breedveld FC, Kalden JR et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor a monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63.
2. Moreland LW. Drugs that block tumour necrosis factor: experience in patients with rheumatoid arthritis. Pharmacoeconomics 2004;22:39-53.
3. Wagner CL, Schantz A, Barnathan E et al. Consequences of immunogenicity to the therapeutic monoclonal antibodies ReoPro and Remicade. Dev Biol (Basel) 2003;112:37-53.
4. Feldmann M, Brennan FM, Foxwell BM et al. Anti-TNF therapy: where have we got to in 2005? J Autoimmun 2005;25 suppl:26-8.
5. Cheifetz A, Mayer L. Monoclonal antibodies, immunogenicity, and associated infusion reactions. Mt Sinai J Med 2005;72:250-6.
6. Anderson P, Louie J, Lau A et al. Mechanisms of differential immunogenicity of tumor necrosis factor inhibitors. Curr Rheumatol Rep 2005;7:3-9.
7. Flendrie M, Creemers MC, Welsing PM et al. Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis. Ann Rheum Dis 2003;62 suppl 2:ii30-ii33.
8. Bendtzen K, Geborek P, Svenson M et al. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor Infliximab. Arthritis Rheum 2006;54:3782-9.
9. Wolbink GJ, Vis M, Lems W et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 2006;54:711-5.
10. Hennig C, Rink L, Fagin U et al. The influence of naturally occurring heterophilic antiimmunoglobulin antibodies on direct measurement of serum proteins using sandwich ELISAs. J Immunol Methods 2000;235:71-80.